帕金森干细胞疗法正式启动II期临床，「睿健医药」获超2亿元融资｜早起看早期

Core Viewpoint - RuiJian Pharmaceutical has recently completed over 100 million yuan in Series B+ financing, led by Fengchuan Capital, to accelerate clinical trials and product development for its core pipeline targeting Parkinson's disease [4][5]. Financing and Growth - The company has raised over 200 million yuan in total from two rounds of Series B financing [5]. - RuiJian Pharmaceutical focuses on the development of small molecule chemical transcription regulation-induced pluripotent stem cell (iPSC) products since its establishment in 2017 [5]. Product Development and Clinical Trials - The core product NouvNeu001, aimed at treating Parkinson's disease, has recently entered Phase II clinical trials [5][6]. - Initial Phase I clinical results showed significant clinical improvement in motor functions and non-motor symptoms in patients after six months of cell transplantation [7]. - The product has demonstrated long-term efficacy, with some patients showing stable improvements in behavior and mobility beyond 60 weeks post-treatment [7]. Future Prospects and Regulatory Approvals - RuiJian Pharmaceutical is also developing NouvNeu003, targeting early-onset Parkinson's patients under 50, which has received approval for Phase I clinical trials [8]. - The company has made progress in overseas clinical research, with NouvNeu001's IND application approved in the U.S. and expected to start Phase I trials soon [8]. Market Position and Investor Insights - The founder and CEO, Dr. Wei Jun, emphasized the company's commitment to addressing clinical needs and providing innovative therapies that can potentially reverse disease progression [9]. - Investors express confidence in RuiJian Pharmaceutical's technology and its potential to become a leading player in the iPSC field, highlighting the significant social and commercial value of its products [10].